艾尔巴韦/格拉瑞韦治疗透析患者1b型丙型肝炎病毒感染的疗效——3例病例报告及文献复习

目的 了解艾尔巴韦/格拉瑞韦治疗丙型肝炎病毒（HCV）1b型感染透析患者的临床疗效及不良反应。方法 回顾性收集3例使用艾尔巴韦/格拉瑞韦抗病毒治疗的HCV 1b型感染透析患者的临床资料，查阅相关文献进行分析、总结。结果 2例血液透析及1例腹膜透析患者采用艾尔巴韦/格拉瑞韦抗病毒治疗，均获得持续病毒应答（SVR12），达到临床治愈标准。1例患者用药4周后出现明显血红蛋白下降，但在治疗12周时改善。1例患者新增疲乏表现，治疗结束后症状消失。治疗中3例患者均未因并发症而停药。结论 使用艾尔巴韦/格拉瑞韦治疗合并HCV 1b型感染的血液透析及腹膜透析患者均有效，且无严重不良反应。

Therapeutic efficacy of elbasvir/grazoprevir in treating hepatitis C virus 1b infection in dialysis patients: three cases report and literature review

Objective To understand the clinical efficacy and adverse reactions of elbasvir/grazoprevir in the treatment of hepatitis C virus (HCV) 1b infection in dialysis patients. Methods Clinical data of 3 dialysis patients with HCV 1b infection who were treated with elbasvir/grazoprevir were collected retrospectively, related literatures were consulted, analyzed and summarized. Results Two hemodialysis patients and one peritoneal dialysis patient were treated with antiviral therapy of elbasvir/grazoprevir, all of them achieved sustained virological response at 12 weeks (SVR12) and achieved the goal of clinical cure. One patient showed a significant decrease in hemoglobin after 4 weeks of treatment, but released after 12 weeks of treatment. Another patient had fatigue during the treatment,symptom disappeared after treatment. None of the three patients stopped the treatment due to complications. Conclusion Elbasvir/grazoprevir is effective for treating HCV 1b infection in hemodialysis and peritoneal dialysis patients, there is no serious adverse reaction.